In vitro metabolism of simvastatin in humans [SBT]identification of metabolizlng enzymes and effect of the drug on hepatic P450S

Drug Metabolism and Disposition

Volumn 25, Issue 10, 1997, Pages 1191-1199

  Prueksaritanont, Thomayant ^a   Gorham, Lynn M ^a   Ma, Bennett ^a   Liu, Lida ^a   Yu, Xiao ^a   Zhao, Jianguo J ^a   Slaughter, Donald E ^a   Arison, Byron H ^a   Vyas, Kamlesh P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LACTONE; LIVER ENZYME; PRODRUG; SIMVASTATIN;

ARTICLE; DRUG CLEARANCE; DRUG METABOLISM; ENZYME INDUCTION; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LIVER MICROSOME; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROSOMES, LIVER; SIMVASTATIN;

EID: 0030812885     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. V. F. Mauro: Clinical pharmacokinetics and practical applications of simvastain. Clin. Pharmacokinet. 24, 195-202 (1993).
2. A. W. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff, C. Hoffman, J. Rothrock, M. Lopez, H. Joshua, E. Harris, A. Patchett, R. Monaghan, S. Currie, E. Stapley, G. Albets-Schonberg, O. Hensens, J. Hirshfield, K. Hoogsteen, J. Liesch, and J. Springer: "Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA 77, 3957-3961 (1980).
3. S. Vickers, C. A. Duncan, K. P. Vyas, P. H. Kari, B. Arison, S. R. Prakash, H. G. Ramjit, S. M. Pitzenberger, G. Stokker, and D. E. Duggan: In vito and in vivo biotransformation of simvastatin. an inhibitor of HMG CoA reductase. Drug Metab. Dispos. 18, 476-483 (1990).
4. H. Cheng, M. S. Schwartz, S. Vickers, J. D. Gilbert, R. D. Amin, B. Depuy, L. Liu, J. D. Rogers, S. M. Pond, C. A. Duncan, T. V. Olah, and W. F. Bayne: Metabolic disposition of simvastatin in patients with T-tube drainage. Drug Metab. Dispos. 22, 139-142 (1994).
5. S. Vickers, C. A. Duncan, I.-W. Chen, A. Rosegay, and D. E. Duggan: Metabolic disposition studies of simvastatin. a cholesterol-lowering prodrug. Drug Metab. Dispos. 18, 138-145 (1990).
6. R. W. Wang, P. H. Kari, A. Y. H. Lu, P. E. Thomas, F. P. Guengerich, and K. P. Vyas: Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 290, 355-361 (1991).
7. F. P. Guengerich and T. Shimadu: Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem. Res. Toxicol. 4, 341-407 (1991).
8. T. Prueksaritanont, L. M. Gorham, J. Hochman, L. Tran, and K. P. Vyas: Comparative studies of drug metabolizing enzymes in dog, monkey and human small intestines and in Caco-2 cells. Drug Metab. Dispos. 24, 634-642 (1996).
9. D. J. Newton, K. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
10. T. K. H. Chang, F. J. Gonzalez, and D. J. Waxman: Evaluation of triacetyloleandromycin. α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 311, 437-442 (1994).
11. H. Yumazaki, Y. Inui, C-H. Yun, F. P. Guengerich, and T. Shimada, Cytochrome P450 2E1. and 2A6: enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13, 1789-1794 (1992).
12. J. A. Goldstein, M. B. Falelto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J. L. Raucy, J. M. Lasker, and B. I. Ghanayem: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33, 1743-1752 (1994).
13. K. H. Thummel, D. D. Shen, T. D. Podoll, K. L. Kunze, W. F. Trager, P. S. Hartwell, V. A. Raisys, C. L. Marsh, J. P. McVicar, D. M. Burr, J. D. Perkins, and R. L. Carithers: Use of midazolam as a human Cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Eep. Ther. 271, 549-556 (1994).
14. J. O. Miners, K. J. Smith, R. A. Robson, M. H. McManus, M. E. Veronese, and D. J. Birkett: Tolbutamide hydroxylation by human liver microsomes. Biochem. Pharmacol. 37, 1137-1144 (1988).
15. K. Chiba, K. Kobayashi, K. Manabe, M. Tam, T. Kamataki, and T. Ishizaki: Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytom 4′-hydroxylation. J. Pharmacol. Exp. Ther. 266, 52-59 (1993)
16. T. Prueksaritanont, L. M. Dwyer, and A. E. Cribb: ( +)-Bufuralol 1′-hydroxylase activity in human and rhesus monkey intestine and liver. Biochem. Pharmacol. 50, 1521-1525 (1995).
17. R. J. Stubbs, M. S. Schwartz, R. J. Gerson, T. J. Thornton, and W. F. Bayne: Comparison of plasma profiles ot Iovastatin (mevinolin). simvastatin (epistatin) and pravastatin (eptastatin) in the dog. Drug Invest. 2(Suppl. 2), 18-28 (1990).
18. S. A. Wrighton, and B. J. Ring: Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole. nifedipine. erythromycin, cimetidine, and nizatidine. Pharm. Res. 11, 921-924 (1994).
19. 4-lovaslatin as a new cytochrome P450 3A catalyzed metabolite of lovastatin in rat and human liver microsomes. ISSX Proc: 4, 35 (1993).
20. T. Prueksaritanont, S. K. Balani, L. M. Dwyer, J. D. Ellis, L. R. Kauffman. S. L. Varga, S. M. Pitzenberger, and A. D. Theoharides: Species differences in the metabolism of a potent HIV-I reverse transcriptase inhibitor L-738,372: In vivo and in vitro studies in rats, dogs, nonkeys. and humans. Drug Metab. Dispos 23, 688-695 (1995).
21. A. Rane. G. R. Wilkinson. and D. G. Shand: Prediction of hepatic extraction from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther: 200, 420-424 (1977).
22. S. A. Wrighton, and J. C. Stevens: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22, 1-21 (1992).
23. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich: Interindividual variations in human liver cylochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
24. C. Wandel, R. Bocker, H. Bohrer, A Browne, E. Rugheimer, and E. Martin: Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br. J. Anaesth. 73, 658-661 (1994).
25. M.-P. Gascon, and P. Dayer: In vitro forcasting of drugs which may interfere with the biotransformation ot midazolam. Eur. J. Clin, Pharmacol. 41, 573-578 (1991).
26. L. L. von Moltke, D. J. Greenblatt, J. Schmider, S. X. Duan, C. H. Wright, J. S. Harmatz, and R. I. Shader: Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol. 36, 783-791 (1996).
27. K. T. Olkkola, J. Ahonen, and P. J. Neuvonen: The effect of the systemic antimycotics. itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Anal. 82. 511-516 (1996).
28. K. T. Olkkola, J. T. Backman, and P. J. Neuvonen: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55, 481-485 (1994).
29. H. Cheng, J. D. Rogers, A. E. Sweany, M. R. Dobrinska, H. A. Stein, A. C. Tate, R. D. Amin, and H. Quan: Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-Coenzyme A (HMGCoA) reductase inhibitors activity following multiple doses of lovastatin and simvastatin. Pharm. Res. 9, 1629-1633 (1992).
30. C. Transon, T. Leemann, and P. Dayer: In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMO-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 50, 209-215 (1996).
31. T. Ikeda, M. Ishigami, T. Komai, Y. Yamazoe, and Y. Ohno: Inhibition of CYP3A by 3-hydroxy-3-methylglularyl-CoA (HMG-CoA) reductase inhibitors. ISSX Proc. 10, 386 (1996).
32. E. Grau, M. Perella, and E. Pastor: Simvastain-oral anticoagulant interaction. Lancet 347, 405-406 (1996).
33. J. J. R. Hermans, and H. H. W. Thijssen: Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br: J. Pharmacol. 110, 482-490 (1993).